CG Oncology CGON
NASDAQ CGON
$67.38 -0.97 (-1.42%)
At close: Oct 2, 2026 · 4:00 PM EDT

CG Oncology (CGON) Price to Sales (2024 - 2026)

Updated

CG Oncology's (CGON) Price to Sales was 1007.41 for Q2 2026, down 72.0% from 3597.15 a year earlier and down 14.2% from the prior quarter.

Analysis

CG Oncology (CGON) Price to Sales (2024 - 2026) Analysis & Trends

For FY2025, Price to Sales at CG Oncology was 829.26, down 47.3% from FY2024.

  • By year, Price to Sales came in at 1573.67 in FY2024.
  • Five-year quarterly Price to Sales spans a low of 829.26 in Q4 2025 and a high of 3833.29 in Q1 2024.
  • Year over year, Price to Sales has now declined in each of the last four quarters, with an average decline of 42.3% over the last six quarters.
  • Per Business Quant data, the three quarters before Q2 2026 came in at 1174.59 (Q1 2026), 829.26 (Q4 2025) and 1450.33 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn
10 CG Oncology 6.04 Bn 6.04 Bn -2.77 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1,007.41
Mar 31, 2026 1,174.59
Dec 31, 2025 829.26
Sep 30, 2025 1,450.33
Jun 30, 2025 3,597.15
Mar 31, 2025 2,819.73
Dec 31, 2024 1,573.67
Sep 30, 2024 3,725.44
Jun 30, 2024 3,237.62
Mar 31, 2024 3,833.29
API Access

CG Oncology Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=CGON&period=max&api_key=YOUR_API_KEY